Skip to main content

Search
Profile

Jane L. Burns, MD

|
Jane L. Burns, MD

Infectious Disease, Pediatrics-Inpatient

On staff since October 1982

Academic Title: Professor, Pediatrics

Research Center: Center for Childhood Infections and Prematurity Research

"For a pediatrician, there is nothing better than to come to work every day in a facility that is totally geared toward children. From the giraffes who greet us at the entrance, to the phlebotomists, medical assistants, X-ray techs and nurses who work so well with kids, what we all do — every day — is support the lives of sick children and their families. What could be better?"

Recommendations

Be the first to recommend Dr. Jane Burns

Overview

Board Certification(s)
Pediatric Infectious Diseases
Pediatrics
Medical/Professional School
University of Washington, Seattle
Residency
Pediatrics, University of Washington, Seattle
Fellowship
Pediatric Infectious Disease, University of Washington, Seattle
Clinical Interests

Cystic fibrosis microbiology, bacterial antibiotic resistance, bone and joint infections

Research Description

My primary area of research for many years has been cystic fibrosis (CF) microbiology, including antibiotic resistance and bacterial pathogenesis. My studies have used both in vitro and in vivo models of infection. Novel methods of in vitro susceptibility testing have been established, including testing drug activity against bacteria grown in biofilms and examining drug bioactivity in the presence of CF sputum. I have worked with both primary CF cells and immortalized cell lines in tissue culture to examine bacterial pathogenesis including attachment, invasion and apoptosis. In vivo experiments use a mouse model of chronic bacterial infections with Pseudomonas aeruginosa and Burkholderia cepacia complex.

My recent work is examining the phenotypic and genotypic adaptations of both organisms to growth within the CF airway. I frequently collaborate with clinical and basic science CF researchers at Seattle Children's Hospital and the University of Washington. In addition, I direct the Center for CF Microbiology at Seattle Children's Hospital, which is a core laboratory for the CF Foundation Therapeutics Development Network.

Research Focus Area

Host: Pathogen Interaction

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Golden Stethoscope AwardSeattle Metropolitan magazine 2008
Named one of Seattle’s “Top Doctors”Named one of Seattle’s “Top Doctors” in Seattle magazine and Seattle Metropolitan magazine 2008
Named one of Seattle’s “Top Doctors”Named one of Seattle’s “Top Doctors” in Seattle magazine 2007
Named one of Seattle’s “Top Doctors”Named one of Seattle’s “Top Doctors” in Seattle magazine and Seattle Metropolitan magazine 2003 - 2006
Frederick C. Moll Prize in Pediatrics 1978
March of Dimes Fellow 1976 - 1977
WAMI Fellow 1975
B.S., Magna cum laude in Biology
Phi Beta Kappa

Publications

Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis.
Journal of clinical microbiology , : : 26-30
Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.
Journal of clinical microbiology , : : 1210-3
Emergence of new pathogens in CF: the devil we know or the devil we don't know?
The Journal of pediatrics , : : 283-4
Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.
Chest , : : 1754-60
Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure.
American journal of kidney diseases : the official journal of the National Kidney Foundation , : : 365-72
Utility of gram staining for evaluation of the quality of cystic fibrosis sputum samples.
Journal of clinical microbiology , : : 2791-4
Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Medical and pediatric oncology , : : 93-8
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine , : : 841-9
Attenuated virulence of a Burkholderia cepacia type III secretion mutant in a murine model of infection.
Infection and immunity , : : 1405-15
Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.
Chest , : : 792-9
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Chest , : : 1495-502
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
Journal of clinical microbiology , : : 4312-7
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
American journal of respiratory and critical care medicine , : : 1471-5
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association , : : 1749-56
Pathophysiology and management of pulmonary infections in cystic fibrosis.
American journal of respiratory and critical care medicine , : : 918-51
Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis.
Environmental microbiology , : : 1341-9
Cepacia-like syndrome caused by Burkholderia multivorans.
The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses , : : 123-5
Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia).
The Journal of clinical investigation , : : 464-73
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Journal of clinical microbiology , : : 1915-22
Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation.
Infection and immunity , : : 5126-34
Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum.
Microbiology (Reading, England) , : : 2947-58
Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness.
The Pediatric infectious disease journal , : : 881-2
Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
Infection and immunity , : : 444-52
Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia.
FEMS microbiology letters , : : 337-44
Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
The Journal of antimicrobial chemotherapy , : : 879-86
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.
The Journal of clinical investigation , : : 436-46
Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides.
Chemical biology & drug design , : : 162-73
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
Proceedings of the National Academy of Sciences of the United States of America , : : 8487-92
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
Pediatric pulmonology , : : 656-65
Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis.
Journal of clinical microbiology , : : 529-35
Anti-inflammatory properties of macrolides.
The Pediatric infectious disease journal , : : 75-6
Association between pulmonary function and sputum biomarkers in cystic fibrosis.
American journal of respiratory and critical care medicine , : : 822-8
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.
Thorax , : : 360-7
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Pediatric pulmonology , : : 533-41
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
Molecular microbiology , : : 512-33
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology , : : 610-23
Pilus-mediated epithelial cell death in response to infection with Burkholderia cenocepacia.
Microbes and infection / Institut Pasteur , : : 829-37
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
The Journal of infectious diseases , : : 1088-92
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Pediatric pulmonology , : : 47-58
Large-insert genome analysis technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patients.
Genomics , : : 530-7
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , : : 66-70
Evolution of Pseudomonas aeruginosa virulence in infected patients revealed in a Dictyostelium discoideum host model
Clin Microbiol Infect , Sept. 2011: 1415-20
Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
Influenza and other respiratory viruses , 2011 Sep 29
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Archives of pediatrics & adolescent medicine , 2011 Sep: 847-56
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , 2011 Aug 9
Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis.
Journal of clinical microbiology , 2011 Jul: 2772-3
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
Pediatric pulmonology , 2011 Feb: 184-92
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.
PloS one , 2011: e23637
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis.
Journal of bacteriology , 2010 Dec: 6191-9
Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Antimicrobial agents and chemotherapy , 2010 Jul: 3024-6
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association , 2010 May 5: 1707-15
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
Pediatric pulmonology , 2010 Apr: 363-70
Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.
PLoS pathogens , 2010 Jan 8: e1000712
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Antimicrobial agents and chemotherapy , 2010 Jan: 143-8
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
The Journal of antimicrobial chemotherapy , 2009 Oct: 829-36
Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation
J Bacteriol , Dec. 2008: 7910-17
Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa
J Bacteriol , Feb. 2003: 1316-25
Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Journal of clinical microbiology , 2003 Jan: 492-4
Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
Infection and immunity , 2002 Mar: 1081-6
Ampicillin use in infant fever: a systematic review.
Archives of pediatrics & adolescent medicine , 2002 Jan: 27-32

Presentations

Presentations TitleEventLocationDate
Newest evidence for management of pediatric urinary tract infectionsNorth Pacific Pediatric Society 183rd Scientific ConferenceCoeur d’Alene, IDAug. 2011
Understanding the clinical microbiology labNACFCBaltimore, MDOct. 2010
Small colony variants in CF: Watch out for the little guysNW ASM Branch MeetingSeattle, WAOct. 2010
The red queen: A history of infectious diseaseNorth Pacific Pediatric Society 180th Scientific ConferenceSeattle, WAMarch 2010
Unique problems in cystic fibrosis microbiologyNorthwest Medical Laboratory Symposium (NWMLS)Seattle, WAOct. 1, 2009
Diagnosis and management of cystic fibrosis airway infectionsGrand Rounds, Hospital for Sick ChildrenToronto, Ontario, CanadaSept. 1, 2009
Molecular diagnostics in cystic fibrosis microbiologySymposium on Respiratory Infections, Novel Research Exploring Diagnosis and Management - SickKids Research InstituteToronto, Ontario, CanadaSept. 1, 2009
CF airway infections - Opponent for Ph.D. dissertation, Elin NilssonUppsala UniversitetStockholm, SwedenMay 1, 2009
Antibiotic susceptibility testing in CFUppsala UniversitetStockholm, SwedenMay 1, 2009
Pathogenesis of cystic fibrosis lung infections, important pathogensKarolinska Universitetssjukhuset CF RegionstudiedagStockholm, SwedenMay 1, 2009
Hypermutability of B. cenocepacia in CFInternational Burkholderia cepacia Working Group (IBCWG)Toronto, CanadaApril 1, 2009
Challenging the paradigm: novel susceptibility testing methods for CFNorth Killarney National Cystic Fibrosis MeetingKillarney, IrelandJan. 2, 2009

Research Funding

Grant TitleGrantorAmountAward Date
Non-invasive detection of Pseudomonas aeruginosa in the exhaled breath of individuals with CFLife Science Discovery FundMay 1, 2011 - April 30, 2012
Mechanism of Azithromycin Activity in Pseudomonas InfectionsNIHJune 15, 2010 - May 31, 2012
Does hypermutability in B. cenocepacia increase virulence in CF?Cystic Fibrosis FoundationApril 1, 2010 - March 31, 2012
Safety and efficacy of aztreonamGilead SciencesJan. 12, 2010 - Jan. 12, 2015
Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatmentNIHSept. 11, 2009 - July 31, 2013
Translational Therapeutics Development CenterCystic Fibrosis Foundation TherapeuticsJan. 1, 2009 - Dec. 31, 2013
Therapeutic Development Center – Microbiology Core LaboratoryCystic Fibrosis Foundation TherapeuticsApril 1, 2008 - Dec. 31, 2011

Primary Office

Seattle Children's Research Institute
C9S - 8 - Infectious Disease
1900 - 9th Ave
Seattle, WA 98101
206-987-2073

Additional Offices

Seattle Children's
MA.7.226 - Infectious Disease Clinic
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2073

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options